# DESCRIPTION

## GOVERNMENT FUNDING

- acknowledge government funding

## TECHNICAL FIELD

- introduce C9orf46 homolog and Plg-RKT

## BACKGROUND

- motivate plasminogen localization
- describe cell surface proteolysis
- summarize macrophage recruitment
- discuss tissue remodeling and wound healing
- mention tumor cell invasion and metastasis
- describe skeletal myogenesis and neurite outgrowth
- discuss apoptosis
- introduce carboxyl-terminal lysines
- describe plasminogen binding sites
- discuss CpB-sensitive plasminogen receptors
- motivate search for integral membrane protein
- describe purification procedure
- introduce multidimensional protein identification technology
- identify C9orf46 homolog/Plg-RKT
- describe Plg-RKT expression and regulation

## BRIEF SUMMARY OF THE INVENTION

- introduce Plg-RKT and its orthologs
- describe Plg-RKT function
- contemplate Plg-RKT polypeptides
- contemplate antibodies
- contemplate methods for detection and identification

## DETAILED DESCRIPTION OF THE INVENTION

### A. Definitions

- define amino acid residue
- define antibody
- define antibody combining site
- define monoclonal antibody
- define lipoprotein(a)
- define plasminogen
- define plasminogen fragments
- define polypeptide and peptide
- define synthetic peptide and tissue plasminogen activator

### B. Polypeptides

- define Plg-RKT polypeptide
- describe Plg-RKT molecule
- specify SEQ ID NO: 1
- introduce embodiment of Plg-RKT polypeptide
- specify SEQ ID NO: 2
- describe capacity of Plg-RKT polypeptide
- introduce related embodiment of Plg-RKT polypeptide
- specify SEQ ID NO: 3
- describe capacity of Plg-RKT polypeptide
- introduce another related embodiment of Plg-RKT polypeptide
- specify SEQ ID NO: 4
- describe capacity of Plg-RKT polypeptide
- introduce further related embodiment of Plg-RKT polypeptide
- specify SEQ ID NO: 5
- describe capacity of Plg-RKT polypeptide
- introduce another related embodiment of Plg-RKT polypeptide
- specify SEQ ID NO: 6
- describe capacity of Plg-RKT polypeptide
- introduce further related embodiment of Plg-RKT polypeptide
- specify SEQ ID NO: 7
- describe capacity of Plg-RKT polypeptide
- introduce another related embodiment of Plg-RKT polypeptide
- specify SEQ ID NO: 8-19
- describe capacity of Plg-RKT polypeptide
- define Plg-RKT polypeptide
- specify sequence and length
- describe preferred polypeptides
- define immunological mimicry
- specify requirements for inhibition
- describe analogs and fragments
- define conservative substitutions
- describe chemical derivatives
- specify changes to polypeptide sequence
- describe additions and deletions
- define fragment
- specify linker residues
- describe terminal modifications
- describe polypeptide cyclization
- describe carrier-hapten conjugate
- define antigenically related variants
- describe pharmaceutically acceptable salts
- specify acids for salt formation
- specify bases for salt formation
- describe synthesis methods
- specify solid-phase synthesis
- describe protective groups
- describe uses of Plg-RKT polypeptide

### C. Antibodies and Monoclonal Antibodies

- define antibody
- define antibody combining site
- define antibody molecule
- describe Fab, Fab', F(ab')2 portions
- describe preparation of Fab, Fab', F(ab')2 portions
- describe preferred antibody molecules
- describe anti-Plg-RKT antibody
- describe immunoreactivity of anti-Plg-RKT antibody
- describe substantially free of antibody molecules
- describe production of anti-Plg-RKT antibody
- describe collection and isolation of antibody molecules
- describe preparation of antibodies against polypeptide
- describe purification of antibodies by immunoaffinity chromatography
- define inoculum
- describe use of polypeptide in inoculum
- describe conjugation of polypeptide to carrier
- describe choice of carrier
- describe preparation of inoculum
- define unit dose
- describe preparation of inocula
- describe use of adjuvants
- describe conjugation of polypeptide through activated functional groups
- describe site-directed coupling reaction
- describe addition of amino acid residues to polypeptide
- describe use of anti-Plg-RKT antibody in therapeutic methods
- define monoclonal antibody
- describe monoclonal antibody composition
- describe production of monoclonal antibody
- describe hybridoma technology
- describe screening of hybridoma supernates
- describe production of monoclonal antibody composition
- describe use of monoclonal antibody in therapeutic, diagnostic, or in vitro methods

### D. Diagnostic Systems

- contemplate diagnostic system
- include Plg-RKT polypeptide and/or antibody
- package reagent with instructions for use
- define package
- describe label or indicating means
- exemplify fluorescent labeling agents
- describe enzyme labeling agents
- describe radioactive labeling agents
- link labels to polypeptides and proteins
- describe specific binding agent
- label specific binding agent
- use specific binding agent as amplifying means
- describe ELISA format
- affix reagent to solid matrix
- describe solid matrices
- provide reagent in solution or dry form
- include enzyme substrate in separate package
- include solid support and buffers in separate packages
- describe packaging materials
- contemplate method for detecting inflammation
- detect Plg-RKT with antibody
- collect body fluid, tissue or cell sample
- exemplify body fluid samples
- contemplate method for detecting inflammation in tissue
- contemplate method for detecting cancer
- detect Plg-RKT with antibody
- collect body fluid, tissue or cell sample
- exemplify body fluid samples
- contemplate method for detecting cancer in tissue
- contemplate method for identifying patients at risk for cancer
- detect Plg-RKT with antibody
- collect body fluid, tissue or cell sample
- exemplify body fluid samples
- contemplate method for identifying patients at risk for metastasis
- detect Plg-RKT with antibody
- collect body fluid, tissue or cell sample
- exemplify body fluid samples
- contemplate method for detecting hematologic disorders
- detect Plg-RKT with antibody
- collect body fluid, tissue or cell sample
- exemplify body fluid samples
- contemplate method for detecting hematologic disorders in tissue
- detect Plg-RKT with antibody
- collect body fluid, tissue or cell sample
- exemplify body fluid samples

### E. Assay Methods

- contemplate immunoassay methods
- form immunoreaction admixture
- maintain under biological assay conditions
- determine amount of Plg-RKT polypeptide-containing immunoreaction product
- relate amount of product to amount of Plg-RKT polypeptide present
- use competitive assay methods
- form immunoreaction product using control sample
- determine amount of product using detection means
- employ biosensors
- detect changes in reflectivity of surface
- detect changes in absorption of evanescent wave
- detect changes in propagation of surface acoustical waves
- contemplate various immunoassay methods for body tissue samples
- detect expression of Plg-RKT
- use microscopic methods
- use immuno-cytological/immunocytochemical methods
- use biochemical methods
- use molecular biological methods
- detect expression of Plg-RKT after enrichment
- use reverse transcription of mRNA
- carry out PCR with primer specific for Plg-RKT
- detect antibody bound to cells

### F. Therapeutic Compositions

- contemplate therapeutic compositions
- contain physiologically tolerable carrier
- contain Plg-RKT polypeptide, antibody, or monoclonal antibody
- inhibit binding of plasminogen, plasminogen fragments, tissue plasminogen activator or lipoprotein(a) to Plg
- prepare pharmacological composition
- mix with excipients
- include pharmaceutically acceptable salts
- include physiologically tolerable carriers

### G. Therapeutic Methods

- inhibit binding of plasminogen, plasminogen fragments, tissue plasminogen activator or lipoprotein(a) to Plg
- reduce inflammation, cancer, and metastasis, and angiogenesis
- administer therapeutically effective amount of composition
- achieve plasma concentration of Plg-RKT polypeptide
- contemplate method for blocking binding of plasminogen, plasminogen fragments, tissue plasminogen activator or lipoprotein(a)
- administer composition containing Plg-RKT polypeptide
- achieve plasma concentration of Plg-RKT polypeptide
- contemplate composition containing Plg-RKT polypeptide
- inhibit plasminogen, plasminogen fragments, tissue plasminogen activator or lipoprotein(a) binding to Plg
- contemplate composition containing Plg-RKT polypeptide
- inhibit plasminogen, plasminogen fragments, tissue plasminogen activator or lipoprotein(a) binding to Plg
- contemplate composition containing Plg-RKT polypeptide
- inhibit plasminogen, plasminogen fragments, tissue plasminogen activator or lipoprotein(a) binding to Plg
- contemplate composition containing antibody
- inhibit plasminogen, plasminogen fragments, tissue plasminogen activator or lipoprotein(a) binding to Plg
- contemplate composition containing antibody
- inhibit plasminogen, plasminogen fragments, tissue plasminogen activator or lipoprotein(a) binding to Plg
- contemplate composition containing antibody
- inhibit plasminogen, plasminogen fragments, tissue plasminogen activator or lipoprotein(a) binding to Plg

## EXAMPLES

- introduce isolation of Plg-RKT
- describe biotinylation of cells
- detail dead cell removal
- outline membrane fraction preparation
- describe plasminogen-Sepharose affinity column
- detail elution and avidin binding
- describe trypsin digestion
- outline MudPIT analysis
- detail tandem mass spectra extraction
- describe binary classifier use
- outline database search
- detail peptide mass search tolerance
- describe SEQUEST algorithm use
- outline peptide/spectrum match assessment
- detail quadratic discriminant analysis
- describe false positive rate determination
- introduce Plg-RKT identification
- describe C9orf46 homolog/Plg-RKT DNA sequence
- detail carboxyl-terminal lysine encoding
- describe CpB treatment effects
- introduce Plg-RKT amino acid sequence
- detail NCBI Blast search
- describe ortholog identification
- outline carboxyl-terminal lysine prediction
- introduce Plg-RKT cell and tissue distribution
- describe high-throughput gene expression profiling
- detail Plg-RKT mRNA microarray expression data
- outline regulation in various tissues
- describe plasminogen binding to carboxyl terminal peptide
- detail peptide synthesis and coating
- describe plasminogen binding assay
- outline antibody detection of Plg-RKT upregulation
- describe antiserum generation
- detail western blotting
- describe partitioning to detergent phase
- outline Triton X-114 phase separation
- describe monoclonal antibody generation
- detail hybridoma selection
- outline plasminogen binding inhibition
- describe inhibitory Plg-RKT polypeptides
- detail peptide synthesis and testing
- describe recognition of Plg-RKT by plasminogen fragments
- introduce monoclonal antibody distinguishing breast cancer cells

